IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.2%
161M of 165M shares
Institutional holders
212
24 new, 36 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 18 sales
Net sold $22.62M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bank Of America Corp /De/ | 9,962,355 | 6.10% | 13G (passive) amendment | Mar 31, 2026 |
| Alexander J. Denner | 9,444,944 | 5.80% | 13D (active) amendment | Mar 17, 2026 |
| State Street Corporation | 8,809,601 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Steven Boyd | 15,028,000 | 9.22% | 13G (passive) amendment | Mar 31, 2026 |
| Armistice Capital, LLC | 13,932,000 | 8.43% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 13,373,568 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Joe M. Thomson | 11,730,771 | 7.32% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IRWD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 17,788,557 | 10.77% | $74.89M | +4,425,627 | 0.00% |
| Armistice Capital, LLC | 13,932,000 | 8.43% | $58.65M | −1,096,000 | 0.72% |
| Sarissa Capital Management LP | 9,188,635 | 5.56% | $38.68M | – | 21.75% |
| State Street Corp | 8,809,601 | 5.33% | $37.09M | +1,352,657 | 0.00% |
| Bank Of America Corp /De/ | 8,683,803 | 5.26% | $36.56M | +896 | 0.00% |
| Renaissance Technologies LLC | 7,993,226 | 4.84% | $33.65M | −67,847 | 0.05% |
| Vanguard Capital Management LLC | 6,608,508 | 4.00% | $27.82M | +511,054 | 0.00% |
| Aqr Capital Management LLC | 6,465,921 | 3.91% | $27.22M | −1,069,159 | 0.01% |
| Acadian Asset Management LLC | 5,853,331 | 3.54% | $24.62K | −723,941 | 0.03% |
| Vanguard Portfolio Management LLC | 5,513,355 | 3.34% | $23.21M | −1,168,682 | 0.00% |
| Geode Capital Management, LLC | 4,831,657 | 2.92% | $20.35M | +288,135 | 0.00% |
| Two Sigma Investments, LP | 4,556,089 | 2.76% | $19.18M | −1,292,187 | 0.01% |
| Marshall Wace, Llp | 4,290,093 | 2.60% | $18.06M | −234,971 | 0.01% |
| Jacobs Levy Equity Management, Inc | 4,065,964 | 2.46% | $17.12M | +433,487 | 0.06% |
| Goldman Sachs Group Inc | 3,313,808 | 2.01% | $13.95M | +623,174 | 0.00% |
| Charles Schwab Investment Management Inc | 3,302,242 | 2.00% | $13.90M | −1,435,615 | 0.00% |
| Federated Hermes, Inc. | 3,231,238 | 1.96% | $13.60M | −117,568 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 3,017,089 | 1.83% | $12.70M | −380,153 | 0.01% |
| Dimensional Fund Advisors LP | 2,522,891 | 1.53% | $10.62M | +440,836 | 0.00% |
| Mackenzie Financial Corp | 2,367,493 | 1.43% | $9.97M | +1,807,459 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 212 | 161M | 97.2% | 24 / 73 | 84 / 36 | 17M | 18M |
| Q1 2026 | 227 | 162M | 97.7% | 57 / 85 | 57 / 25 | 44M | 22M |
| Q4 2025 | 199 | 155M | 93.6% | 56 / 63 | 48 / 18 | 19M | 13M |
| Q3 2025 | 166 | 149M | 90.0% | 30 / 53 | 47 / 18 | 14M | 12M |
| Q2 2025 | 155 | 146M | 88.5% | 19 / 59 | 52 / 64 | 29M | 38M |
| Q1 2025 | 200 | 156M | 94.1% | 30 / 74 | 63 / 51 | 37M | 45M |
| Q4 2024 | 223 | 164M | 99.4% | 41 / 78 | 77 / 37 | 15M | 14M |
| Q3 2024 | 221 | 164M | 99.1% | 39 / 69 | 77 / 44 | 37M | 23M |
| Q2 2024 | 227 | 173M | 100.0% | 21 / 93 | 80 / 51 | 18M | 23M |
| Q1 2024 | 261 | 179M | 100.0% | 54 / 85 | 84 / 43 | 43M | 33M |
| Q4 2023 | 251 | 169M | 100.0% | 32 / 87 | 94 / 26 | 22M | 13M |
| Q3 2023 | 248 | 160M | 96.6% | 38 / 78 | 101 / 40 | 18M | 25M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IRWD | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,499,839 | 3.33% | $23.15M | 0.22% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,781,484 | 2.89% | $20.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,262,458 | 2.58% | $17.94M | 0.02% | Jun 30, 2026 |
| Schwab Fundamental U.S. Small Company ETF | 2,465,723 | 1.49% | $8.80M | 0.10% | May 31, 2026 |
| Vanguard Strategic Equity Fund | 1,833,231 | 1.11% | $7.72M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,790,034 | 1.08% | $7.57M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,677,797 | 1.02% | $7.06M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,413,903 | 0.86% | $5.95M | 0.04% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,403,741 | 0.85% | $5.94M | 0.03% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,286,341 | 0.78% | $5.44M | 0.24% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,116,521 | 0.68% | $4.70M | 0.05% | Jun 30, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 1,079,411 | 0.65% | $4.57M | 0.12% | Jul 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 904,987 | 0.55% | $3.81M | 0.03% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 833,504 | 0.50% | $2.98M | 0.06% | May 29, 2026 |
| Vanguard Russell 2000 Index Fund | 823,033 | 0.50% | $2.94M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas A. MCCOURT | Chief Executive Officer, Director | 1,898,838 | 1.15% | Mar 12, 2026 |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 137,036 | 0.08% | Jul 22, 2026 |
| Ronald Silver | PFO & PAO | 755,250 | 0.46% | Jul 9, 2026 |
| Tammi L. Gaskins | Chief Commercial Officer | 350,350 | 0.21% | Mar 12, 2026 |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 1,179,462 | 0.71% | Mar 12, 2026 |
| Minardo John | Chief Legal Officer | 500,498 | 0.30% | Mar 12, 2026 |
| Gregory S. Martini | Chief Financial Officer | 297,213 | 0.18% | Mar 12, 2026 |
| Sravan Kumar Emany | SVP, COO and CFO | 309,572 | 0.19% | Nov 20, 2024 |
| Andrew Davis | SVP, Chief Business Officer | 284,685 | 0.17% | Nov 20, 2024 |
| Alexander J. Denner | Director | 18,710,619 | 11.32% | Sep 17, 2026 |
| Jay Shepard | Director | 235,036 | 0.14% | Jun 17, 2026 |
| Jon R. Duane | Director | 253,820 | 0.15% | Jun 17, 2026 |
| Julie McHugh | Director | 410,693 | 0.25% | Jun 17, 2026 |
| Mark G. Currie | Director | 676,900 | 0.41% | Jun 17, 2026 |
| Catherine Moukheibir | Director | 181,425 | 0.11% | Jun 17, 2026 |
| Marla L. Kessler | Director | 229,364 | 0.14% | Jun 17, 2026 |
| Andrew Dreyfus | Director | 228,313 | 0.14% | Jun 12, 2025 |
| Capital Management LP Sarissa | 10% owner | 16,625,962 | 10.06% | Dec 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexander J. Denner Director | Sep 15, 2026 | Award | +3,694 | – | – | 327,549 |
| Jeffrey Silber SVP, CMO, Head-Res&Drug | Jul 20, 2026 | Award | +137,036 | – | – | 137,036 |
| Ronald Silver PFO & PAO | Jul 7, 2026 | Sale(10b5-1 plan) | −127,890 | $4.52 | $578.06K | 313,680 |
| Alexander J. Denner Director | Jun 16, 2026 | Award | +63,481 | – | – | 323,855 |
| Julie McHugh Director | Jun 16, 2026 | Award | +63,481 | – | – | 272,320 |
| Julie McHugh Director | Jun 16, 2026 | Sale(10b5-1 plan) | −21,571 | $3.73 | $80.46K | 250,749 |
| Mark G. Currie Director | Jun 16, 2026 | Award | +63,481 | – | – | 676,900 |
| Marla L. Kessler Director | Jun 16, 2026 | Award | +63,481 | – | – | 229,364 |
| Catherine Moukheibir Director | Jun 16, 2026 | Award | +63,481 | – | – | 181,425 |
| Jay Shepard Director | Jun 16, 2026 | Award | +63,481 | – | – | 235,036 |
| Jon R. Duane Director | Jun 16, 2026 | Award | +63,481 | – | – | 253,820 |
| Alexander J. Denner Director | Jun 15, 2026 | Award | +4,065 | – | – | 260,374 |
| Ronald Silver PFO & PAO | May 19, 2026 | Award | +25,000 | – | – | 441,570 |
| Alexander J. Denner Director | Mar 17, 2026 | Sale | −6,725,000 | $3.05 | $20.51M | 9,194,435 |
| Alexander J. Denner Director | Mar 17, 2026 | Sale | −5,800 | $3.31 | $19.20K | 9,188,635 |
| Alexander J. Denner Director | Mar 13, 2026 | Award | +4,451 | – | – | 256,309 |
| Minardo John Chief Legal Officer | Mar 10, 2026 | Award | +136,612 | – | – | 500,498 |
| Ronald Silver Principal Accounting Officer | Mar 10, 2026 | Award | +163,934 | – | – | 416,570 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Mar 10, 2026 | Award | +409,836 | – | – | 1,898,838 |
| Tammi L. Gaskins Chief Commercial Officer | Mar 10, 2026 | Award | +136,612 | – | – | 350,350 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Mar 10, 2026 | Award | +136,612 | – | – | 658,037 |
| Gregory S. Martini Chief Financial Officer | Mar 10, 2026 | Award | +136,612 | – | – | 297,213 |
| Gregory S. Martini Chief Financial Officer | Feb 24, 2026 | Sale | −11,457 | $3.66 | $41.93K | 160,601 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Feb 24, 2026 | Sale | −103,526 | $3.66 | $378.91K | 1,489,002 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 24, 2026 | Sale | +17,012 | $3.66 | $62.26K | 521,425 |
| Ronald Silver Principal Accounting Officer | Feb 24, 2026 | Sale | −12,621 | $3.66 | $46.19K | 252,636 |
| Minardo John Chief Legal Officer | Feb 24, 2026 | Sale | −19,053 | $3.66 | $69.73K | 363,886 |
| Tammi L. Gaskins Chief Commercial Officer | Feb 24, 2026 | Sale | −11,239 | $3.66 | $41.13K | 213,738 |
| Gregory S. Martini Chief Financial Officer | Feb 23, 2026 | Sale | −10,487 | $3.81 | $39.96K | 172,058 |
| Thomas A. MCCOURT Chief Executive Officer, Director | Feb 23, 2026 | Sale | −94,757 | $3.81 | $361.02K | 1,592,528 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 23, 2026 | Sale | −15,570 | $3.81 | $59.32K | 538,437 |
| Ronald Silver Principal Accounting Officer | Feb 23, 2026 | Sale | −11,552 | $3.81 | $44.01K | 265,257 |
| Minardo John Chief Legal Officer | Feb 23, 2026 | Sale | −17,439 | $3.81 | $66.44K | 382,939 |
| Tammi L. Gaskins Chief Commercial Officer | Feb 23, 2026 | Sale | −10,287 | $3.81 | $39.19K | 224,977 |
| Ronald Silver Principal Accounting Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −35,416 | $4.60 | $162.91K | 276,809 |
| Alexander J. Denner Director, 10% owner | Dec 15, 2025 | Award | +4,178 | – | – | 251,858 |
| Tammi L. Gaskins Chief Commercial Officer | Nov 17, 2025 | Sale | −6,016 | $3.32 | $19.97K | 235,264 |
| Alexander J. Denner Director, 10% owner | Sep 15, 2025 | Award | +11,718 | – | – | 247,680 |
| Minardo John Chief Legal Officer | Aug 11, 2025 | Sale | −7,754 | $0.84 | $6.51K | 400,378 |
| Ronald Silver Principal Accounting Officer | Aug 11, 2025 | Sale | −2,846 | $0.84 | $2.39K | 276,809 |
| Tammi L. Gaskins Chief Commercial Officer | Aug 11, 2025 | Sale | −1,316 | $0.84 | $1.11K | 241,280 |
| Gregory S. Martini Chief Financial Officer | Aug 11, 2025 | Sale | −1,265 | $0.84 | $1.06K | 182,545 |
| Capital Management LP Sarissa 10% owner | Jun 13, 2025 | Award | +24,193 | – | – | 235,962 |
| Julie McHugh Director | Jun 10, 2025 | Award | +45,000 | – | – | 208,839 |
| Catherine Moukheibir Director | Jun 10, 2025 | Award | +45,000 | – | – | 117,944 |
| Mark G. Currie Director | Jun 10, 2025 | Award | +45,000 | – | – | 613,419 |
| Andrew Dreyfus Director | Jun 10, 2025 | Award | +45,000 | – | – | 228,313 |
| Alexander J. Denner Director, 10% owner | Jun 10, 2025 | Award | +45,000 | – | – | 211,769 |
| Jon R. Duane Director | Jun 10, 2025 | Award | +45,000 | – | – | 190,339 |
| Jay Shepard Director | Jun 10, 2025 | Award | +45,000 | – | – | 171,555 |
| Marla L. Kessler Director | Jun 10, 2025 | Award | +45,000 | – | – | 165,883 |
| Thomas A. MCCOURT Chief Executive Officer, Director | May 20, 2025 | Award | +540,000 | – | – | 1,687,281 |
| Tammi L. Gaskins Chief Commercial Officer | May 16, 2025 | Sale | −2,563 | $0.58 | $1.49K | 242,596 |
| Thomas A. MCCOURT Chief Executive Officer, Director | May 16, 2025 | Sale | −13,353 | $0.58 | $7.74K | 1,147,281 |
| Capital Management LP Sarissa 10% owner | Apr 2, 2025 | Award | +10,416 | – | – | 166,769 |
| Ronald Silver Principal Accounting Officer | Feb 10, 2025 | Sale | −12,048 | $1.76 | $21.20K | 279,655 |
| Minardo John Chief Legal Officer | Feb 10, 2025 | Award | +122,222 | – | – | 447,070 |
| Minardo John Chief Legal Officer | Feb 10, 2025 | Sale | −38,938 | $1.76 | $68.53K | 408,132 |
| Gregory S. Martini Chief Financial Officer | Feb 10, 2025 | Sale | −12,052 | $1.76 | $21.21K | 183,810 |
| Michael Shetzline SVP, CMO, Head-Res&Drug | Feb 10, 2025 | Sale | −41,269 | $1.76 | $72.63K | 554,007 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael Shetzline Former Officer | Sep 23, 2026 | 83,306 | $377.38K | Sep 24, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan |
| Silver Ronald Officer | Jul 7, 2026 | 127,890 | $560.16K | Jul 7, 2026 | Restricted Stock Units |
| McHugh Julie Director | Jun 16, 2026 | 21,571 | $79.60K | Jun 16, 2026 | Restricted Stock Units |
| Gregory S. Martini Officer | Feb 20, 2026 | 20,163 | $92.95K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | Feb 20, 2026 | 19,775 | $91.16K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Thomas A. MCCOURT Officer, Director | Feb 20, 2026 | 182,185 | $839.87K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Minardo John Officer | Feb 20, 2026 | 33,528 | $154.56K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Michael Shetzline Officer | Feb 20, 2026 | 29,937 | $138.01K | Feb 23, 2026 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Silver Ronald Officer | Jan 5, 2026 | 35,416 | $151.23K | Jan 5, 2026 | Employee Stock Purchase Plan |
| Tammi L. Gaskins Officer | Nov 14, 2025 | 6,324 | $21.31K | Nov 17, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Minardo John Officer | Aug 8, 2025 | 8,281 | $7.29K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | Aug 8, 2025 | 1,406 | $1.24K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Gregory S. Martini Officer | Aug 8, 2025 | 1,351 | $1.19K | Aug 11, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements |
| Thomas A. MCCOURT Officer, Director | May 16, 2025 | 14,661 | $8.65K | May 19, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |
| Tammi L. Gaskins Officer | May 16, 2025 | 2,814 | $1.66K | May 19, 2025 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements |